RSV vaccine trial seeks to boost immunity understanding
NCT ID NCT07618325
First seen Jun 10, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This study will test a new RSV vaccine in 60 adults aged 20 and older. The goal is to understand how the vaccine triggers the immune system, including antibody and T-cell responses. Researchers hope this will lead to better RSV vaccines in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
What this could lead to
If successful, this could help develop a more effective RSV vaccine by revealing how the immune system responds to it.
What could go wrong
This is an early-stage study with only 60 participants, so results may not apply to larger populations. The vaccine may not produce strong enough immune responses.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.